COMP <GO>
AKBA vs JNJ // EV/EBITDA & P/E VALUATION
Akebia Therapeutics Inc. (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: AKBA 4
— JNJ 6
▲ EV/EBITDA & P/E VALUATION LEADER: AKBA
LAST: $0.71 (-4.81%) • MKT CAP: $205.7M
valuation
4.3x
LAST: $273.20 (-0.73%) • MKT CAP: $662.49B
valuation
18.5x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (AKBA VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | AKBA | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 83.30% | 67.90% | +15.40 | AKBA | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 85.00% | 25.50% | +59.50 | AKBA | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 4.3x | 18.5x | -14.20 | AKBA | /valuation <GO> |
| Free Cash Flow Yield | — | 2.97% | — | TIE | /fcf-yield <GO> |
| Operating Margin | 9.90% | 34.70% | -24.80 | JNJ | /operating-margins <GO> |
| Net Profit Margin | -2.20% | 28.50% | -30.70 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | 47.50% | 6.00% | +41.50 | AKBA | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | 5.59 | -5.39 | JNJ | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 8/9 | -1.00 | JNJ | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 45.2 | 62.1 | -16.89 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.08 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 23.0x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $205.7M | $662.49B | -$662.29B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | AKBA REV | JNJ REV | AKBA GROSS % | JNJ GROSS % | AKBA FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $236.2M | $94.19B | 83.3% | 67.9% | $67.7M | $19.70B |
| FY 2024 | $160.2M | $88.82B | 60.6% | 69.1% | -$40.7M | $19.84B |
| FY 2023 | $194.6M | $85.16B | — | — | -$23.4M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
AKBA // BETA —
JNJ // BETA 1.08